-
-
The Cost of Attacking the Pharmaceutical Industry
Trump
Trump's policies during his second term have rocked the U.S. scientific community, slashing NIH funding, threatening pharmaceutical innovation, and reshaping the global research landscape amid rising concerns about America's future in science.
-
NIH Cuts and the Future of U.S. Biopharma
NIH
Trump's proposed NIH budget cuts, agency consolidations, and funding restrictions could reshape U.S. biomedical research, strain U.S.-China collaborations, and shift national priorities toward AI and space tech.
-
Trump's Presidency: Impact on the U.S. Biopharma Industry
FDA
Explore the implications of Trump's return on U.S. biopharma: healthcare cost reforms, IRA adjustments, reshoring manufacturing, and FDA/NIH shifts. Key focus areas for Chinese pharma include supply chain resilience and navigating new cross-border data regulations.
-
-
Tecovirimat Ineffective for Clade I Mpox in DRC Study
NIH
A recent NIH study in the Democratic Republic of the Congo found that tecovirimat does not improve clade I mpox lesion resolution. Despite this, mortality rates were lower than average. The study emphasizes the need for more research on effective treatments and vaccines for clade I mpox.
-
-
-
-
桃江县|
拜城县|
石首市|
滨海县|
侯马市|
大姚县|
揭阳市|
抚顺县|
礼泉县|
康马县|
金华市|
尉犁县|
梧州市|
唐河县|
库尔勒市|
汶川县|
五台县|
宁乡县|
宜兰市|
永定县|
子长县|
阳信县|
来宾市|
博乐市|
调兵山市|
札达县|
古交市|
通州市|
始兴县|
榕江县|
和田市|
浑源县|
苏尼特左旗|
都兰县|
台北县|
灵石县|
葫芦岛市|
东阿县|
遂平县|
岳阳市|
黄梅县|